Efficient myelin regeneration in the central nervous system (CNS) requires the migration, proliferation and differentiation of oligodendrocyte progenitor cells (OPC) into myelinating oligodendrocytes. In demyelinating diseases such as multiple sclerosis (MS), this regenerative process can fail, and therapies targeting myelin repair are currently completely lacking in the clinic.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT

Regenerative immunology
The roles of T cells in inflammatory demyelinating diseases such as Multiple Sclerosis (MS) have been well-studied in recent decades. These research efforts have resulted in the development of around a dozen disease-modifying therapies for MS, many of which target T cell development, function and trafficking. Animal models of T cell-mediated demyelination have underpinned much of this research and the range of models of experimental autoimmune encephalomyelitis (EAE) have become the most widely used models, not only of MS, but of autoimmune disease in general. As such, neuroimmunology research has greatly informed inflammation biology in general. Among some of the key advances that have resulted from EAE studies are the pathogenic functions of effector T helper (Th)1 and Th17 cells and the potent immunoregulatory capacity of suppressor T cells, more commonly now referred to as regulatory T cells (Treg) (Legroux and Arbour, 2016) . These cells are potent anti-inflammatory cells that can target a range of inflammatory mechanisms (Kitagawa and Sakaguchi, 2017) . However, as will be discussed later, Treg exert more than just anti-inflammatory influence. Recent studies have pinpointed a variety of Treg mechanisms that directly and indirectly boost tissue regeneration, opening up new avenues for the development of regenerative therapeutics based on T cell biology.
The topic of regenerative immunology is an emerging, and rapidly progressing field. The roles of immune responses in tissue regeneration can be largely categorised into mechanisms that support resolution of inflammation, which can indirectly support tissue regeneration, and direct regenerative mechanisms affecting non-immune cells such as stem and progenitor cells locally. Given the capacity for immune cells to exert such effects, the immune system holds immense potential to promote tissue regeneration. If we understand how the immune system naturally supports efficient tissue regeneration, this knowledge can be harnessed to develop new regenerative therapies. It is clear that the immune system can also be inhibitory to tissue regeneration and promote scarring and fibrosis, or even sustain immunopathological damage. In this regard, blocking immune signals that impair regenerative responses also holds therapeutic potential to promote regeneration. There exist cells that co-express Foxp3 and other CD4 + subset canonical transcription factors such as T-bet or RORγt (Ayyoub et al., 2009; Hall et al., 2013; Oldenhove et al., 2009) (Benacerraf et al., 1975; Gershon and Kondo, 1970) . The concept of suppressive T cells largely fell out of favour for quite some time but gained resurgence in the 1990s (Sakaguchi et al., 1995) . The identification of Foxp3 as the canonical transcription factor driving Treg development (Fontenot et al., 2003; Hori et al., 2003) accelerated a field that uncovered immunoregulatory functions of Treg at an astounding pace. Treg were identified to inhibit the actions of virtually all pro-inflammatory immune cells including T and B lymphocytes, dendritic cells and macrophages.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
Mechanisms of suppression included secretion of soluble factors (e.g. IL-10, TGF-β and IL-35), cellcontact-dependent actions, direct cytolysis (e.g. granzyme-mediated killing), competition for proinflammatory signals needed to initiate and/or sustain pro-inflammatory immune responses (e.g. IL-M A N U S C R I P T
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2, CD80/CD86, MHC-II) and inhibition of antigen presenting cell maturation (reviewed in Shevach, 2018 (Gandolfo et al., 2009) . In a mouse model of oxygen-induced retinopathy, immunoregulatory functions of Treg have been shown to promote vascular repair (Deliyanti et al., 2017) . Treg have also been identified to promote skin wound healing as depletion of Treg in vivo delayed wound closure and affected blood vessel maturation (Haertel et al., 2018; Nosbaum et al., 2016) .
Treg have been shown to directly support regeneration of skeletal muscle, myelin, lung, myocardium, bone, and hair follicles (discussed in more detail below). Within these tissues different Treg cellular mechanisms and soluble factors have been implicated in accomplishing effective tissue regeneration. This is not surprising considering the diversity of progenitor cells in these different tissues and the distinct mechanisms that govern responses of these different cell types to damage in the respective tissue type (see Figure 1) . Investigation of regenerative Treg mechanism in the central nervous system (CNS) will benefit from studies in other tissues which have been reported in recent years.
The groups of Mathis and Benoist elegantly revealed a role for Treg in muscle regeneration. Using a mouse model of cardiotoxin-induced muscle damage they showed that mice deficient in Treg showed impaired satellite cell differentiation and muscle regeneration. Furthermore, Treg-derived amphiregulin (AR) was critical in this setting (Burzyn et al., 2013) . This group went on to show impaired Treg recruitment to lesioned muscle in aged mice, indicating that enhancing Treg recruitment may be a therapeutic goal to enhance tissue regeneration in the aged (Kuswanto et al., M A N U S C R I P T A C C E P T E D (Castiglioni et al., 2015) . In a mouse model of myocardial infarction, depletion of Treg exacerbated cardiac inflammation and tissue damage while expansion of Treg in vivo using anti-CD28 superagonist after injury, reduced ventricular rupture and skewed monocytes/macrophages to a pro-regenerative M2-like phenotype (Weirather et al., 2014) .
Furthermore, the Frangogiannis group showed a direct effect of Treg on the cardiac fibroblast phenotype and function as Treg reduced the contraction of collagen pads by cardiac fibroblasts and reduced both α-smooth muscle actin and MMP3 in an in vitro co-culture system (Saxena et al., 2014) . Within the lung, Treg supported type II alveolar epithelial cell (AT2) proliferation and promoted lung epithelial barrier regeneration. Furthermore, KGF was identified as a critical Tregderived factor that drives AT2 cell proliferation (Dial et al., 2017; Mock et al., 2014) . Skin-resident
Treg directly promoted hair follicle stem cell (HFSC) regeneration via notch signaling through Treg Jagged1, which enhanced HFSC proliferation and differentiation (Ali et al., 2017) . Treg have been
shown to impact bone resorption, an important process in continuous skeletal remodeling. Foxp3-overexpression, expansion of Treg numbers with CD28-specific superagonistic antibody or adoptive transfer of Treg into Rag1 -/-mice resulted in increased bone mass and density due to decreased osteoclast numbers and decreased bone resorption (Zaiss et al., 2010b (Zaiss et al., , 2010a . In addition, human
Treg inhibited osteoclast differentiation via TGF-β and IL-4 (Kim et al., 2007) and CTLA-4 was shown to regulate human osteoclast precursor numbers and osteoclastogenesis. Furthermore, engagement of CD80/86 through soluble CTLA-4 or co-culture with Treg inhibited osteoclast differentiation (Bozec et al., 2014) . In 2017 we also uncovered a direct regenerative role for murine Treg in myelin regeneration in the CNS (Dombrowski et al., 2017) , a tissue once thought to have very limited regenerative capacity. This emphasises the breadth and potency of regenerative Treg functions and opens new possibilities of developing neuroregenerative therapies, a key unmet need in neurological disease and ageing.
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susceptible to damage by trauma or (auto)immune attacks, the latter a characteristic feature of many demyelinating diseases (Bradl and Lassmann, 2010; Young et al., 2013) . Immune attacks can destroy entire myelin sheaths and kill oligodendrocytes leaving axons stripped bare and susceptible to neurodegeneration. MS is the most common demyelinating disease with around 2.5 million patients affected worldwide (Pugliatti et al., 2002) . The hallmarks of this still incurable disease are demyelinated lesions throughout the brain, spinal cord and optic nerve as a result of immunemediated attacks against myelin; the underlying cause that triggers the disease, however, is still not well understood (Lassmann, 2014; Trapp et al., 1998) .
Remyelination is a physiological process that efficiently replaces lost myelin throughout life in healthy individuals (Franklin and ffrench-Constant, 2017) . Remyelination involves the recruitment of immature oligodendrocyte progenitor cells (OPC) to areas of damaged myelin, followed by proliferation and differentiation of OPC into myelin-producing oligodendrocytes that then extend newly formed myelin membranes around demyelinated axons (Franklin and Barnett, 1997) . In demyelinating diseases such as MS, however, the regenerative capacity of oligodendrocytes declines with disease progression and can be lost entirely, leading to neurodegeneration and irreversible loss of function causing severe disability and morbidity for patients (Chang et al., 2002; Franklin and ffrench-Constant, 2008) . Kuhlmann et al. uncovered oligodendrocyte differentiation failure as a key bottleneck for efficient remyelination in chronic MS lesions as demonstrated by the presence of proliferating OPC in up to 80% of non-remyelinating lesions (Kuhlmann et al., 2008) . Others identified reduced numbers of OPC in the demyelinated lesions in both animal models and human demyelinated tissue Sim et al., 2002; Wolswijk, 2002) indicating that any of the above steps could be dysregulated in non-remyelinating lesions; the underlying mechanisms for successful remyelination, however, are still not completely understood.
Even beyond the CNS, tissue regeneration-promoting pharmacological agents hold immense potential to restore function and reduce morbidity and mortality in a range of diseases. Such regenerative therapies are largely lacking and stem cell-based therapies are a main area of focus in this regard. However any such therapy, be it cell-based or pharmacological, must function in a setting of tissue damage that is usually heavily influenced by robust immune responses to this damage. Thus, it is critical to understand the immunological players that influence tissue regeneration. Ageing is a universal impediment to efficient tissue regeneration and the global ageing M A N U S C R I P T
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population emphasizes the need to develop effective regenerative therapies, particularly in neurological disease.
While in the past two decades many disease-modifying therapies such as beta-interferon have been introduced to reduce relapse rates for many MS patients, these drugs are largely not effective for progressive MS and treatments that restore myelin remain experimental. This highlights the urgent need for remyelination therapies and recent experimental efforts have focused on identifying the cellular and molecular mechanisms driving myelin regeneration in order to identify novel remyelination targets. Numerous intrinsic and extrinsic factors that promote or inhibit OPC migration, proliferation and oligodendrocyte differentiation have been identified over the past two decades. These include growth factors such as PDGFα or activin-A, semaphorins, membrane proteins such as Lingo or CXCR2, interleukins such as LIF and CCN family members such as CCN3 (Dombrowski et al., 2017; Fischer et al., 2014; Lindner et al., 2008; Mi et al., 2007; Miron et al., 2013; Williams et al., 2007; Woodruff et al., 2004 ). Yet, these experimental approaches warrant confirmation of translational efficiency in clinical trials with MS patients. The use of high throughput screening methods has further accelerated the testing of preclinical remyelination drugs. Deshmukh et al.
identified benztropine in OPC differentiation high throughput screening (Deshmukh et al., 2013) , while Mei et al. identified clemastine as a potential remyelination drug using a micropillar screening approach (Mei et al., 2014) . Njim et al. identified clobetasol and miconazole as remyelination promoting agents (Najm et al., 2015) . Several remyelination approaches that were successful in preclinical models are being evaluated in clinical trials such as clemastine (Mei et al., 2014) in ReCOVER and ReBUILD (Plemel et al., 2017) . Furthermore, cell-based therapies with bone marrow derived stem cells (ACTiMuS) and mesenchymal stem cells (MESEMS) are under investigation in phase I/II trials. However, the efficacy of these stem cell approaches is largely thought to be
immunomodulatory. These studies demonstrate the growing range of approaches to develop regenerative therapies in MS (Plemel et al., 2017) .
One of the most innovative approaches of new experimental remyelination methodologies is exploiting the capacity of the immune system to enhance tissue regeneration. This is particularly intriguing as immune cells, in particular T cells such as Th1 and Th17 cells, can orchestrate the immune-mediated attack leading to myelin damage in the CNS while cells of the innate immune system such as macrophages and microglia can execute and enhance myelin destruction (Baxi et al., 2015; Yamasaki et al., 2014) . In MS, remyelination is associated with areas of inflammation; however if this is cause or correlation remains to be determined (Raine and Wu, 1993; Setzu et al., 2006) .
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Nonetheless, experimental evidence suggests that inflammation is beneficial for remyelination and cells of both the innate and adaptive immune systems are required for efficient myelin regeneration (Arnett et al., 2003; Dombrowski et al., 2017; El Behi et al., 2017; Kotter et al., 2001; Miron et al., 2013; Patani et al., 2007; Ruckh et al., 2012; Schwartz et al., 1999) . For instance, macrophages and microglia promote remyelination in animal models of MS (Doring et al., 2015; Kotter et al., 2001; Miron et al., 2013) and the lack of B and T cells reduced remyelination efficiency in vivo (Bieber et al., 2003) . Both B and T cell compartments consist of a variety of subtypes and in MS, Th1 and Th17 cells are implicated in disease pathology (Lassmann, 2014; Trapp et al., 1998) , while Treg dampen immune responses by controlling inflammatory effector T cells. This diversity of T cell function has been demonstrated in both MS and associated animal models (Constantinescu et al., 2011; Costantino et al., 2008; Plaisted et al., 2016; Sakaguchi, 2000; Setzu et al., 2006; Sospedra and Martin, 2016) . Yet for over a decade it remained unclear which lymphocyte population was the key cell type necessary for remyelination as reported previously (Bieber et al., 2003) . However, with major advances in anti-inflammatory MS therapies during this time it was not surprising that the focus shifted somewhat away from this initial discovery. Recently, we have identified a key role of Treg in remyelination beyond known immunomodulatory functions of these cells (Dombrowski et al., 2017) . In MS, Treg frequency is similar to that of healthy individuals, though Treg suppressor function is impaired (Viglietta et al., 2004) . Furthermore, lymphocytes from MS patients differentially promote oligodendrocyte proliferation in a mouse model of demyelination (El Behi et al., 2017) . Treg were described in regeneration of other tissues (discussed earlier) and are important for recovery from experimental spinal cord injury (Raposo et al., 2014) , furthermore, we showed that Treg directly regulate a regenerative process in the CNS.
To categorically distinguish between Treg modulation of inflammatory myelin damage and the function of Treg in myelin regeneration we used an experimental model of MS that clearly distinguishes de-and remyelination phases. Injection of lysolecithin toxin directly into spinal cord white matter induces a focal lesion of demyelination which spontaneously and efficiently remyelinates during the following month (Hall, 1972) . The regenerative phase in this model is well characterised and follows the steps of OPC recruitment into the lesion, differentiation of OPC into myelin-producing oligodendrocytes and finally, remyelination -wrapping and compaction of myelin around demyelinated axons (Hall, 1972) . The well-defined timecourse of myelin regeneration in this model allows separation of damaging and regenerative phases, which is not possible in the commonly used experimental autoimmune encephalomyelitis (EAE) model, where de-and M A N U S C R I P T
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remyelination can happen concomitantly. Thus, it is not easy to distinguish the stage of lesion derived from EAE tissue; demyelinated, demyelinating, remyelinating or remyelinated lesions. Using the lysolecithin model we found that Treg were required for efficient remyelination as mice lacking Treg had significantly fewer remyelinated axons. This correlated with reduced numbers of differentiated oligodendrocytes in the lesions of these mice, indicating that Treg impact the critical step of oligodendrocyte differentiation (Dombrowski et al., 2017) . This effect was mediated by the Treg secretome as Treg-conditioned media enhanced OPC differentiation in vitro but had no impact on OPC proliferation (Dittmer et al., 2018; Dombrowski et al., 2017) . Treg secretome screening revealed CCN3 as a protein highly enriched in Treg-conditioned media but not in that from Foxp3 -T cells. In vitro neutralisation and depletion studies identified CCN3 as a factor that mediated the promyelinating Treg effect (Dombrowski et al., 2017 ) (see Figure 2 ). This not only identified CCN3 as a protein targeting OPC differentiation but was also the first report that described CCN3 production in Treg, or indeed any T cells. This extends the known immunomodulatory role of Treg in the CNS to now include myelin regenerative functions. How our findings translate to human MS remains to be uncovered.
CCN proteins
CCN3 belongs to a family of matricellular proteins known as the CCN family, largely associated with the extracellular matrix (ECM) and involved in a wide range of biological signaling pathways. The family was named after the original nomenclature given to the first three identified members, in chronological order: Cysteine-rich angiogenic protein 61 (CYR61), Connective tissue growth factor (CTGF) and Nephroblastoma overexpressed (NOV) -now known as CCN1, CCN2 and CCN3 respectively (Joliot et al., 1992; O'Brien et al., 1990; Ryseck et al., 1991) . These proteins were unified in nomenclature after it was observed that they shared similar structural features (Bork, 1993) . Thereafter, three more members were identified. These peptides were initially named Wnt-1 Inducible Signaling Pathway Proteins 1-3 (WISP 1-3), and later changed to CCN4, CCN5 and CCN6 respectively (Brigstock et al., 2003; Hashimoto et al., 1998; Pennica et al., 1998; Zhang et al., 1998) . Regardless of the structural similarities, these proteins carry out very distinct and sometimes opposing functions depending on the protein and tissue in question.
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The primary peptide chain of CCN proteins contains 343-381 amino acids. These polypeptides can generate products of 35 to 40 kDa in size (with larger molecular weight when subjected to post-translational modifications) consisting of 38 conserved cysteine amino acids, which are organized into four modules (Brigstock, 1999) . From the primary amino acid sequences, it was observed that these modules shared similarity with Insulin-like growth factor-binding proteins (IGFBP), a type C repeat of von Willebrand factor (VWC), a type 1 repeat of thrombospondin (TSP1) and a C-terminal domain (CT) (Perbal, 2004 ) (see Figure 3) . Additionally, there is a signal peptide (SP) located at the N-terminus of the proteins, which led to the finding that many CCN proteins are secreted (Perbal, 2013) . Each of these modules is encoded by a distinct exon, and most CCN genes have five exons.
Exceptions to this organization include CCN5, which lacks a CT domain, and CCN6, which lacks four of the conserved cysteine residues in the VWC module. The existence of a hinge region between VWC and TSP1 modules and reports that CCN2 is post-translationally modified into shorter isoforms (Ball et al., 1998) , led to speculation that these proteins have the potential for proteolytic cleavage.
The functions carried out by CCN proteins are extremely diverse, and depending on the cell type, some functions can be antagonistic. These include differentiation, development, cell cycle control, tissue repair and regeneration, inflammation, connective tissue scarring (fibrosis), ECM synthesis and degradation, cell migration and adhesion (Perbal and Takigawa, 2005) . Unsurprisingly, due to heavy involvement of CCN proteins in cell cycle control, these proteins play a critical role in many types of cancer -such as gastric, ovarian, breast, prostate, oesophageal, colorectal, bone and brain tumours (reviewed in Chen and Lau, 2009) . It is worth noting that there is discussion regarding whether CCN functions are due to the action of individual modules or combinations of modules. Proteins can also form homomeric or heteromeric complexes with other CCN members or even proteins from other families, which adds complexity to the study of CCN family in the context of cell biology (discussed in Perbal, 2018) .
Roles of CCN proteins in the CNS
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There is substantial evidence that matricellular proteins play important roles in the CNS.
Investigation into the expression and function of CCN proteins in the CNS is a developing field and sometimes contradictory. Nevertheless, the growing body of literature in this field provides an insight into CCN function in the CNS during development, adulthood, tissue damage and regeneration. Currently, there is evidence of expression and functions of CCN1-5 in the CNS but not yet for CCN6 (see Figure 4) . CCN proteins are widely expressed in the developing and mature CNS (reviewed in Malik et al., 2015) .
Evidence suggests that CCN1 is a positive regulator of dendritic arborisation in developing rat hippocampal neurons in vitro. CCN1 knockdown in developing neurons reduced dendritic arborisation and total dendritic length, however no effect was observed in mature neurons (Malik et al., 2013) . Overexpression of CCN1 in both developing and mature neurons, increased dendrite numbers and CCN1 positively regulated this neuronal dendrite increase through β1-integrin signaling (Malik et al., 2013) . CCN1 has also been shown to play a role in to increased survival of embryonic hippocampal neural progenitor cells (Kim et al., 2003) .
These findings demonstrated a role for CCN1 in neuronal apoptosis. Contrary to this, CCN1
has been described to promote retinal photoreceptor survival by interacting with Müller glia and the retinal pigment epithelium (RPE) by promoting Akt, ERK1, ERK2 and STAT3
phosphorylation. This phosphorylation was suggested to cause transcriptional changes in
Müller glia and RPE, leading to the secretion of neuroprotective factors that directly affect photoreceptor cell survival (Kucharska et al., 2014) .
CCN2 regulates inhibitory neuron survival in the glomerular layer of the olfactory bulb (OB) in postnatal mice. CCN2 was secreted by external tufted cells and decreased the survival of M A N U S C R I P T
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periglomerular inhibitory neurons by promoting apoptosis through TGF-β2. Changes in CCN2 expression levels in the OB modified local neuronal circuitry and olfactory behaviours (Khodosevich et al., 2013) . Recently, a negative regulatory role for CCN2 in CNS myelination has been elucidated, which will be discussed later.
CCN3 was shown to be expressed by Purkinje neurons and negatively regulated granule neuron precursor cell (GNP) proliferation during cerebellar development. CCN3 blocked sonic hedgehog (SHH)-mediated GNP proliferation through GSK3-β activity, which in turn downregulated N-Myc, a driver of GNP proliferation. This anti-proliferative function of CCN3
in GNPs was attributed to interaction with integrins containing the β3 subunit. In addition to modulating proliferation, this study reported that CCN3 stimulates GNP chemotaxis. Based on these findings, the authors hypothesised that CCN3 could be a potential player in GNP maturation (Le Dréau et al., 2010) . CCN3 has also been reported to play a role in neurite growth inhibition in Neuro2A cells (Park et al., 2015) and to be expressed during chick retinal development mainly (but not exclusively) by Müller cells in vivo and in vitro. This expression was induced by BMP signalling and downregulated by Notch signalling in Müller cell cultures, and the authors discussed that CCN3 could play a role in Müller cell biology in the developing and adult retina (Maryvonne et al., 2012) . Interestingly, CCN3 was found to have a positive role in oligodendrocyte differentiation and developmental myelination which will be discussed later in more detail (Dombrowski et al., 2017) .
CCN4 was shown to prevent neuronal injury and apoptosis during oxidative stress exposure in vitro. CCN4 required activation of the PI3K and Akt1 pathways to enhance neuronal cell survival. Through these pathways, CCN4 promoted phosphorylation of Bad and GSK-3β, reduced Bim/Bax and increased Bcl-xL/Bax complex expression. CCN4 prevented mitochondrial membrane permeability, cytochrome c release, and caspase 3 activity in the presence of oxidative stress (Wang et al., 2012) . These results suggest that CCN4 plays a role in neuronal survival.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
In contrast to CCN3, CCN5 was shown to promote neurite formation in Neuro2a cells.
Recombinant CCN5 treatment induced Akt phosphorylation by interacting with integrin β1.
Moreover, CCN5 overexpression promoted neuronal survival in cells challenged with the neurotoxic agent H 2 O 2 (Ohkawa et al., 2011) . These results suggest that CCN5 may play a role in neurite formation and neuronal survival.
Roles of CCN3 in tissue regeneration
We reported a novel function of Treg-derived CCN3 in oligodendrocyte differentiation and myelination, supporting previous findings of CCN3 pro-regenerative functions in other tissues. CCN3 plays a role in inflammation resolution, which is crucial for efficient tissue regeneration. CCN3 acted as a negative regulator of vascular inflammation and promoted inflammatory response resolution in vascular endothelial cells and tissues (Lin et al., 2010; Liu et al., 2014; Zhang et al., 2016; Shi et al., 2017) as well as in the kidney (Marchal et al., 2015) and DRG neurons (Kular et al., 2012) suggesting that CCN3 can support efficient tissue regeneration via multiple mechanisms.
Direct injection of CCN3 into the rat cornea induced neovascularization demonstrating the pro-angiogenic function of this protein (Lin et al., 2003) . CCN3 secreted from prostate cancer cells induced polarisation of M1-like macrophages to an M2-like phenotype, which is a key immunological switch that reduces inflammation and promotes tissue repair . Prostate cancer cell-derived CCN3 promoted focal adhesion kinase signaling, resulting in VEGF upregulation and tube formation by endothelial progenitor cells . CCN3 was identified to be essential for hematopoietic stem cell (HSC) renewal in humans. CCN3 is essential for maintaining HSC long term repopulating activity and bone marrow engraftment (Gupta et al., 2007) . Finally, CCN3 is also known to participate in chondrogenesis (Heath et al., 2008; Hoshijima et al., 2012; Janune et al., 2017 Janune et al., , 2011 Kawaki et al., 2008; Lafont et al., 2005; Roddy and Boulter, 2015) , osteogenesis (Heath et al., 2008; Matsushita et al., 2013; Minamizato et al., 2007; Ouellet and Siegel, 2012; Rydziel et al., 2007) and dentin regeneration .
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Roles of CCN2 and CCN3 in myelin development and regeneration
For the first time, we found evidence that Treg-derived CCN3 enhances oligodendrocyte differentiation and myelination. Even though this is the case in ex vivo and in vitro models containing other cells from the CNS, CCN3 is dispensable for the direct effects of Treg on oligodendrocyte differentiation (our unpublished observations). This suggests that CCN3-induced oligodendrocyte differentiation enhancement could be mediated through a different cell type such as microglia, neurons or astrocytes. Alternatively, CCN3 could interact with extracellular matrix components to facilitate enhanced OPC differentiation. As previously mentioned, neuron-derived CCN2 negatively regulates myelination. It was found that knocking out neuronal SRF in mice led to downregulation of myelin gene expression and myelination impairment. In this setting, CCN2 expression was upregulated, and this upregulation inhibited oligodendrocyte differentiation by blocking IGF1, a known enhancer of oligodendrocyte differentiation (Stritt et al., 2009) . Supporting these findings, Tsc1 or Tsc2 knockdown in neurons led to a hypomyelination phenotype, similar to that observed in tuberous sclerosis patients. CCN2 was upregulated in neurons lacking Tsc1 and Tsc2 and it was proposed that this may be due to the downregulation of its transcription factor repressor SRF (Ercan et al., 2017) . Finally, inhibiting neuronal CCN2 rescued hypomyelination in the setting of Tsc deficiency. This identified CCN2 as a neuronal regulator of myelination, and a target of the mTOR pathway (Ercan et al., 2017) . More recently, it was demonstrated that treatment of hSOD1 G93A mice (Amyotrophic Lateral Sclerosis mouse model) with a CCN2 neutralising antibody (FG-3019) delayed disease onset, improved locomotor function, decreased myofiber atrophy and increased neuromuscular junction innervation. Treatment of hSOD1 G93A mice with FG-3019 also decreased myelin degeneration in the sciatic nerve compared to IgG-treated controls (Gonzalez et al., 2018) .
Taken together, these results demonstrate a negative regulatory role of CCN2 in myelination. Although some of the mechanisms behind the negative regulation of myelination by CCN2 have been elucidated, it remains unknown how CCN3 promotes oligodendrocyte differentiation and myelination. CCN3 exerts some of its biological functions through several receptors in non-CNS cells, including Notch1 (Sakamoto et al., 2002) , integrins α6β1, αvβ3, αvβ5 and α5β1 (reviewed in Chen and Lau, 2009) Interestingly, CCN2 and CCN3 have been shown to exert reciprocal regulation of expression in different tissues. For instance, knocking out CCN2 in chondrocytes strongly upregulates CCN3 expression. This upregulation leads to a decrease in chondrocyte proliferation (Kawaki et al., 2008) . CCN3 has also been reported to directly bind CCN2 and regulate the expression of cartilaginous matrix genes in a chondrosarcoma cell line (Hoshijima et al., 2012) . CCN3 is robustly expressed in neurons of the adult and developing rodent CNS (Su et al., 2001 ; our unpublished observations), hence it is tempting to hypothesise that there is inter-regulation between neuronal CCN2 and CCN3 to control oligodendrocyte differentiation. Taken together, these findings reinforce the increasing evidence that ECM and ECM-associated components play a crucial role in OPC migration, proliferation and differentiation (Lau et al., 2013) . This opens up an exciting avenue of research into CCN proteins for remyelination therapies.
Conclusion
The potential impact of regenerative therapies in neurological disease is vast and recent studies discussed here suggest that immune mechanisms may hold considerable potential to develop such therapies. Elucidating how immune cells naturally promote inflammatory lesion resolution, stem and progenitor development and ultimately, regeneration of functional tissue will provide knowledge to drive regenerative drug development programmes for therapeutic gain. The recent focus on the adaptive immune system, in particular T cells in regeneration, has pointed to a range of T cell mechanisms that benefit tissue regeneration. The diversity of mechanisms in varied tissues is striking and some common mechanisms in different tissues suggest that T cell-derived regenerative therapies may be applicable to a range of debilitating diseases. Some of these mechanisms discovered in peripheral tissues may well be relevant in the CNS, and this may accelerate the development of therapies for neurological disease including MS. However, it is imperative to study T cell-driven tissue regeneration in the CNS also, to ensure that CNS-specific T cell 
